NASDAQ
Jade Biosciences, Inc. (JBIO)
♥ 435 Thanks from members
Jade Biosciences, Inc. (JBIO) commands a strong consensus 'Buy' rating from major Wall Street institutions, driven by promising clinical progress for its lead IgA nephropathy candidate JADE101, substantial liquidity, and a robust balance sheet offsetting near-term pre-revenue unprofitability.